- Home
- PRQR
as 11-22-2024 4:00pm EST
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 309.5M | IPO Year: | 2014 |
| Target Price: | $7.13 | AVG Volume (30 days): | 635.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.18 - $4.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | $20,506,357 | Revenue Growth: | 306.68% |
| Revenue Growth (this year): | 298.83% | Revenue Growth (next year): | -8.80% |
Latest ProQR Therapeutics N.V. News
PRQR Breaking Stock News: Dive into PRQR Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
TipRanks
15 days ago
ProQR Therapeutics sees cash runway into mid-2027
GlobeNewswire
16 days ago
ProQR Announces Third Quarter 2024 Operating and Financial Results
GlobeNewswire
a month ago
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
GlobeNewswire
a month ago
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
GlobeNewswire
a month ago
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
Simply Wall St.
a month ago
Gevo And 2 Other US Penny Stocks To Watch Closely
Simply Wall St.
a month ago
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year
Compare PRQR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.